Dermapharm Holding SECHIX:DMPD 80 3-Year ROIIC % is 1.87 as of Dec. 2025, which is 36% below its 10-year median of 2.93. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €38.59. The stock has 9 warning signs investors should review. Among 941 Drug Manufacturers companies, Dermapharm Holding SE ranks worse than 53.77% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Dermapharm Holding SE's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1.87%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Dermapharm Holding SE's 3-Year ROIIC % or its related term are showing as below:
CHIX:DMPd's 3-Year ROIIC % is ranked worse than 53.77% of 941
companies
in the Drug Manufacturers industry
Industry Median: 3.7
vs CHIX:DMPd: 1.87
Dermapharm Holding SE (CHIX:DMPd) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Dermapharm Holding SE 3-Year ROIIC % Related Terms
Dermapharm Holding SE 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Dermapharm Holding SE's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DMPD vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Dermapharm Holding SE (CHIX:DMPD) has a 3-Year ROIIC % of 1.87 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Dermapharm Holding SE and its competitors. This is 36% below median its historical median of 2.93. According to the industry distribution chart, Dermapharm Holding SE ranks #506 out of 941 companies in the Drug Manufacturers industry, placing it in the top 53.8%.
Is Dermapharm Holding SE's 3-Year ROIIC % too high?
Dermapharm Holding SE's current 3-Year ROIIC % of 1.87 is 36% below median its 10-year median of 2.93. The Drug Manufacturers industry median 3-Year ROIIC % is 3.70. Dermapharm Holding SE's value of 1.87 is 49.5% below this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #506 out of 941 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #506 out of 941 companies for 3-Year ROIIC %. This places Dermapharm Holding SE in the lower half of its industry. The industry median 3-Year ROIIC % is 3.70. Dermapharm Holding SE's value of 1.87 is 49.5% below this benchmark. While the company's 10-year median is 2.93 vs. the industry median of 3.70, Dermapharm Holding SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.70, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current 3-Year ROIIC % of 1.87 is 49.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current 3-Year ROIIC % is 1.87, which is 36% below median its own 10-year median of 2.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current 3-Year ROIIC % of 1.87. The stock's GF Value™ is €38.59, compared to a current price of €46.18 — trading 19.7% above its estimated fair value. The current 3-Year ROIIC % is 1.87, which is 36% below median its 10-year median of 2.93 and 49.5% below the Drug Manufacturers industry median of 3.70. Dermapharm Holding SE's overall GF Score™ is 80/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current 3-Year ROIIC % is 1.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 19.7% above its estimated GF Value™ of €38.59.
Key valuation signals for CHIX:DMPD:
3-Year ROIIC %: 1.87 (36% below median its 10-year median of 2.93)
GF Value™: €38.59 vs. price of €46.18 (19.7% above fair value)
Industry Position: 49.5% below the Drug Manufacturers median (#506 of 941)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
